Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (330)	9/1/1998 1:21:00 PM
From: mauser96	Read Replies (1) \| Respond to of 645

OUCH! There's a company conference call with analysts going on right now. Maybe all the cows left Texas... :-) IMHO,the general market rally going on now is a sucker rally. At the very least we will retest old lows. Of course this opinion is probably worth what you paid for it <g>

To: Arthur Radley who wrote (330)	9/1/1998 2:50:00 PM
From: Gerald Walls	Read Replies (1) \| Respond to of 645

From the news, it appears there is a problem with manufacturing, but could be more. From the news release there doesn't appear to be a problem. The FDA just wants more info. Fortunately I sold this for a profit a couple of weeks ago. biz.yahoo.com The company on Monday said the U.S. Food and Drug Administration had not accepted its marketing application for FluMist because the agency needed more information on the manufacturing processes and the facilities where the vaccine will be manufactured. ... The company said Monday that the agency was not seeking any additional information on safety or efficacy of the vaccine. But it added that the FDA might require another clinical trial to ''bridge'' from the manufacturing process used for producing small amounts of the vaccine in the Phase III trial to the process planned for producing larger commercial supplies. ... 'The real nuts and bolts of FluMist, its safety and efficacy, do not appear to be an issue,'' Van Den Broek said. ''What Aviron needs to show is that its manufacturing situation is in order -- that it can replicate the same product in far larger amounts. And companies generally resolve these types of manufacturing issues,'' Van Den Broek added.